Bio-Techne Corporation announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The platform enables the design of protein-based solutions to overcome variability and scalability challenges by improving stability and activity of critical reagents. These additions build on Bio-Techne's strategy following an earlier expansion of the portfolio, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists. Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota, stated that "IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies." Will Geist, President of Bio-Techne, said the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows, supporting scale-up from discovery through production.